GR3036642T3 - Novel benzoyl guanidines, their production and their use in medicaments - Google Patents

Novel benzoyl guanidines, their production and their use in medicaments

Info

Publication number
GR3036642T3
GR3036642T3 GR20010401500T GR20010401500T GR3036642T3 GR 3036642 T3 GR3036642 T3 GR 3036642T3 GR 20010401500 T GR20010401500 T GR 20010401500T GR 20010401500 T GR20010401500 T GR 20010401500T GR 3036642 T3 GR3036642 T3 GR 3036642T3
Authority
GR
Greece
Prior art keywords
pct
medicaments
production
novel benzoyl
benzoyl guanidines
Prior art date
Application number
GR20010401500T
Other languages
English (en)
Inventor
Otto Roos
Georg Speck
Walter Loesel
Dietrich Arndts
Wolf-Dietrich Bechtel
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of GR3036642T3 publication Critical patent/GR3036642T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR20010401500T 1993-11-04 2001-09-18 Novel benzoyl guanidines, their production and their use in medicaments GR3036642T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4337611A DE4337611A1 (de) 1993-11-04 1993-11-04 Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
PCT/EP1994/003581 WO1995012584A1 (de) 1993-11-04 1994-10-31 Neue benzoylguanidine, ihre herstellung und ihre verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
GR3036642T3 true GR3036642T3 (en) 2001-12-31

Family

ID=6501758

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401500T GR3036642T3 (en) 1993-11-04 2001-09-18 Novel benzoyl guanidines, their production and their use in medicaments

Country Status (20)

Country Link
US (1) US5783576A (el)
EP (1) EP0733046B1 (el)
JP (1) JPH09504535A (el)
KR (1) KR100359676B1 (el)
CN (1) CN1056609C (el)
AT (1) ATE202563T1 (el)
AU (1) AU687911B2 (el)
CA (1) CA2175838A1 (el)
CO (1) CO4290417A1 (el)
DE (2) DE4337611A1 (el)
DK (1) DK0733046T3 (el)
ES (1) ES2157993T3 (el)
GR (1) GR3036642T3 (el)
NZ (1) NZ274849A (el)
PL (1) PL180302B1 (el)
PT (1) PT733046E (el)
RU (1) RU2136659C1 (el)
TW (1) TW400319B (el)
WO (1) WO1995012584A1 (el)
ZA (1) ZA948670B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
CA2325471C (en) * 1998-03-23 2010-08-17 Aventis Pharmaceuticals Products Inc. Piperididinyl and n-amidinopiperidinyl derivatives
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6706732B1 (en) 1999-06-03 2004-03-16 Takeda Chemical Industries, Ltd. Nasal preparation of guanidinoimino quinoline derivatives
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
BR0309398A (pt) * 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
AU2003270489A1 (en) * 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7189723B2 (en) * 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) * 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005019220A2 (en) * 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP2397478A1 (en) * 2005-01-14 2011-12-21 CGI Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity.
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EA020461B1 (ru) 2008-12-08 2014-11-28 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk
PE20120121A1 (es) * 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP5938352B2 (ja) 2010-03-11 2016-06-22 ギリアード コネチカット， インコーポレイテッド イミダゾピリジンｓｙｋ阻害剤
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
PL3027171T3 (pl) 2013-07-30 2020-08-24 Gilead Connecticut, Inc. Formulacja inhibitorów syk
AU2014360537B2 (en) 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
EP4605391A1 (en) * 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953476A (en) * 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
SU1114021A1 (ru) * 1982-11-11 1995-12-20 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 4-метоксибензилгуанидин или его сернокислая соль, оказывающие ингибирующее действие на моноаминоксидазу мозга
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP0589336B1 (de) * 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
ES2100435T3 (es) * 1992-12-16 1997-06-16 Hoechst Ag Aminobenzoilguanidinas 3,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.

Also Published As

Publication number Publication date
CN1134146A (zh) 1996-10-23
PL180302B1 (pl) 2001-01-31
NZ274849A (en) 1998-08-26
DK0733046T3 (da) 2001-09-03
PT733046E (pt) 2001-10-30
HK1010722A1 (en) 1999-06-25
KR960705789A (ko) 1996-11-08
CO4290417A1 (es) 1996-04-17
AU7993794A (en) 1995-05-23
RU2136659C1 (ru) 1999-09-10
WO1995012584A1 (de) 1995-05-11
EP0733046B1 (de) 2001-06-27
DE59409794D1 (de) 2001-08-02
US5783576A (en) 1998-07-21
ATE202563T1 (de) 2001-07-15
ES2157993T3 (es) 2001-09-01
CN1056609C (zh) 2000-09-20
ZA948670B (en) 1995-07-04
EP0733046A1 (de) 1996-09-25
JPH09504535A (ja) 1997-05-06
AU687911B2 (en) 1998-03-05
CA2175838A1 (en) 1995-05-11
PL314188A1 (en) 1996-09-02
DE4337611A1 (de) 1995-05-11
TW400319B (en) 2000-08-01
KR100359676B1 (ko) 2003-04-16

Similar Documents

Publication Publication Date Title
AU687911B2 (en) Novel benzoyl guanidines, their production and their use in medicaments
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
IL111861A (en) Phenyl-n-substituted azabicycloalkene derivatives and pharmaceutical compositions containing them
IL116385A0 (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
IL111077A (en) Pyridine derivatives processes for the preparation thereof and pharmaceutical compositions containing them
ZA949593B (en) N-substituted azabicycloheptane derivatives their preparation and use
IL105454A0 (en) Water-soluble retinoids,their preparation and pharmaceutical and cosmetic compositions containing them
HUT76271A (en) Substituted aminoalkylaminopyridines, process for producing them and their use
NO952308D0 (no) Anvendelse av ruluzoler som radiorestaurator

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees